GC Biopharma (006280 KS/Buy)2Q26 Preview: Earnings Set to Improve in 2H

113 Views25 Jul 2026 08:02

Broker

We expect GC Biopharma to post below-consensus 2Q26 results, with revenue of W418.7bn (-16.3% YoY; vs. consensus of W473.6bn) and operating profit of W4.2bn (-84.7% YoY; vs. consensus of W15bn).

What is covered in the Full Insight:

2Q26 Financial Performance
Factors Impacting Earnings
Future Outlook and Guidance
Target Price and Rating
Curevo Sale and Financial Strategy

Mirae Asset Securities

SUMMARY

(Sign Up to Access)

Try Now

Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:

Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

SMARTKARMA PREVIEW PASS

By signing up, you agree to our
Terms of Use and Privacy Policy.

Already have an account? Sign In Now

Full Insight

(Paid Plans Only, 15-minute read)

Discussions

(Paid Plans Only)

Price Chart(Sign Up to Access)

Insight Stream

GC Biopharma (006280 KS/Buy)2Q26 Preview: Earnings Set to Improve in 2H
25 Jul 2026